Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro

Mistletoe lectin is thought to constitute the active principle in extract preparations from mistletoe, which are widely used as immunomodulators in adjuvant tumor therapy. However, no study exists which compares the immunological potency of different well‐defined mistletoe lectin preparations on human immune cells. Therefore, in the present study the biological effects of an aqueous mistletoe extract, standardized for mistletoe lectin I (eML), the isolated natural mistletoe lectin (nML), and the recombinant form of this lectin (rML) on human peripheral blood monocytes and lymphocytes were compared with respect to cell viability and cytokine induction. After 48‐hr incubation of peripheral blood mononuclear cells (PBMC) with rML, nML, and eML, a continuous concentration‐dependent decrease in cell viability was found with an IC50 of about 3 ng/ml for rML and nML and 10 ng/ml for eML, respectively. This effect also was seen when isolated lymphocytes and monocytes were separately incubated with the lectin preparations. After incubation of PBMC and isolated monocytes of 5/10 blood donors with eML, an increase in cell viability was found at lectin concentrations between 10 and 1,000 pg/ml. This effect was not seen with the pure lectin preparations nML and rML. After 48‐hr incubation of PBMC with rML, nML, and eML, induction of IL‐1‐β, TNF‐α, IL‐2, IL‐6, and IL‐10 but not IFN‐γ was measured. For IL‐1‐β it could be shown that cytokine induction took place at a broad lectin concentration range (0.1–100 ng/ml). Cytokine levels varied greatly in the PBMC cultures of the different blood donors. When monocytes were separately incubated with eML, nML, and rML for 48 hr, high levels of IL‐1‐β were found. In contrast, in cultures of separated lymphocytes from the same donors only a minimal production of IL‐1‐β and no production of IFN‐γ was found after incubation with rML, nML, and eML. It is concluded that there are quantitative differences in the immunomodulatory effects of the mistletoe lectin preparations on human monocytes and lymphocytes. Therefore, measurement of cell viability and cytokine induction may be a diagnostic laboratory tool to determine the immunological potency of various mistletoe preparations and may help to clarify the clinical benefit of therapies with these substances. J. Clin. Lab. Anal. 14:255–259, 2000. © 2000 Wiley‐Liss, Inc.

[1]  J. Eck,et al.  Characterization of recombinant and plant-derived mistletoe lectin and their B-chains. , 1999, European journal of biochemistry.

[2]  J. Eck,et al.  Cloning of the mistletoe lectin gene and characterization of the recombinant A-chain. , 1999, European journal of biochemistry.

[3]  C. Betzel,et al.  Primary Structure and Molecular Modeling of Mistletoe Lectin I fromViscum album , 1998 .

[4]  C. Betzel,et al.  Primary structure and molecular modeling of mistletoe lectin I from Viscum album. , 1998, Biochemical and Biophysical Research Communications - BBRC.

[5]  J. Eck,et al.  Effects of mistletoe lectin I on human blood cell lines and peripheral blood cells. Cytotoxicity, apoptosis and induction of cytokines. , 1997, Arzneimittel-Forschung.

[6]  P. Berg,et al.  Mistletoe extract-induced effects on immunocompetent cells: in vitro studies , 1997, Anti-cancer drugs.

[7]  R. Anton,et al.  Modulation of cytotoxicity and enhancement of cytokine release induced by Viscum album L. extracts or mistletoe lectins , 1997, Anti-cancer drugs.

[8]  R. Saller,et al.  Immunomodulatory effects of Viscum album agglutinin-l on natural immunity , 1997, Anti-cancer drugs.

[9]  H. Gabius,et al.  Concepts of tumor lectinology. , 1997, Cancer investigation.

[10]  W. Voelter,et al.  Complete amino acid sequence of the A chain of mistletoe lectin I , 1996, FEBS letters.

[11]  P. Poindron,et al.  Mistletoe lectins I, II and III induce the production of cytokines by cultured human monocytes. , 1996, Cancer letters.

[12]  M. Ishiyama,et al.  A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. , 1996, Biological & pharmaceutical bulletin.

[13]  A. Büssing,et al.  Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins. , 1996, Cancer letters.

[14]  P. Berg,et al.  Evaluation of the stimulatory activity of a fermented mistletoe lectin-1 free mistletoe extract on T-helper cells and monocytes in healthy individuals in vitro. , 1996, Arzneimittel-Forschung.

[15]  R. Saller,et al.  A natural immunity-activating plant lectin, Viscum album agglutinin-I, induces apoptosis in human lymphocytes, monocytes, monocytic THP-1 cells and murine thymocytes. , 1996, Natural immunity.

[16]  R. Herrmann,et al.  A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. , 1995, Natural immunity.

[17]  J. Kleijnen,et al.  Mistletoe treatment for cancer review of controlled trials in humans. , 1994, Phytomedicine.

[18]  J. Beuth,et al.  Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients. , 1994, Anticancer research.

[19]  H. Gabius,et al.  The sugar-combining area of the galactose-specific toxic lectin of mistletoe extends beyond the terminal sugar residue: comparison with a homologous toxic lectin, ricin. , 1994, Carbohydrate research.

[20]  S. Joshi,et al.  From ill-defined extracts to the immunomodulatory lectin: will there be a reason for oncological application of mistletoe? , 1994, Planta medica.

[21]  V. Bocci.  Mistletoe (viscum album) lectins as cytokine inducers and immunoadjuvant in tumor therapy. A review. , 1993, Journal of biological regulators and homeostatic agents.

[22]  H. Franz,et al.  Identity of the N‐terminal sequences of the three A chains of mistletoe (Viscum album L.) lectins: homology with ricin‐like plant toxins and single‐chain ribosome‐inhibiting proteins , 1992, Anti-cancer drugs.

[23]  S. Hauser,et al.  Unproven methods in oncology. , 1991, European journal of cancer.

[24]  S. von Kleist,et al.  Evaluation of a test system for measuring cytokine production in human whole blood cell cultures. , 1991, Journal of immunological methods.

[25]  K. Frei,et al.  Increased Secretion of Tumor Necrosis Factor α, Interleukin 1, and Interleukin 6 by Human Mononuclear Cells Exposed to β-Galactoside-specific Lectin from Clinically Applied Mistletoe Extract , 1990 .

[26]  S. Baudino,et al.  Characterization of cytotoxic proteins from mistletoe (Viscum album L.). , 1990, Cancer letters.

[27]  H. Franz,et al.  The site of action of the A‐chain of mistletoe lectin I on eukaryotic ribosomes The RNA N‐glycosidase activity of the protein , 1988, FEBS letters.

[28]  J. Filicetti.  Unproven methods of cancer treatment , 1987, AAOHN journal : official journal of the American Association of Occupational Health Nurses.